NCT06213636
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). No drug interventions treatment 1 / 2 recruiting NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia treatment 1 terminated NCT06463691
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients treatment 2 not_yet_recruiting NCT05176691
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 withdrawn NCT05414162
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy No drug interventions Not Available Not Available recruiting NCT05788289
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma No drug interventions treatment 2 terminated NCT05214183
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT06192888
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma No drug interventions treatment 1 recruiting NCT03625037
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma No drug interventions treatment 1 / 2 active_not_recruiting NCT02488512
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas No drug interventions treatment 2 terminated NCT04913103
Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL No drug interventions treatment 2 not_yet_recruiting NCT01221103
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) No drug interventions treatment 1 / 2 unknown_status NCT06427213
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma treatment 2 not_yet_recruiting NCT05659732
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer No drug interventions treatment 1 recruiting NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) treatment 2 active_not_recruiting NCT03647124
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma Not Available Not Available recruiting NCT05564052
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma treatment 2 active_not_recruiting NCT04036448
A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea Not Available Not Available completed NCT02669017
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) No drug interventions treatment 1 completed NCT02454270
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies No drug interventions treatment 1 terminated NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors No drug interventions treatment 1 / 2 terminated NCT02278796
A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) No drug interventions treatment 2 completed NCT01786135
A Safety Study of SGN-CD19A for B-Cell Lymphoma No drug interventions treatment 1 completed NCT00514722
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies No drug interventions treatment Not Available terminated NCT00420056
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma. No drug interventions treatment 1 completed NCT00209209
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL treatment 3 unknown_status NCT00702052
Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy No drug interventions treatment 2 completed NCT06136351
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT05172700
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer No drug interventions Not Available Not Available available NCT05155215
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT04911478
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells No drug interventions Not Available Not Available enrolling_by_invitation NCT04735471
A Phase 1 Study of ADI-001 in B Cell Malignancies No drug interventions treatment 1 recruiting NCT04662255
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) No drug interventions treatment 3 active_not_recruiting NCT03476655
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India No drug interventions Not Available Not Available completed NCT05024045
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers No drug interventions treatment 1 active_not_recruiting NCT05431179
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 3 withdrawn NCT02743546
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma No drug interventions treatment 1 withdrawn NCT02455297
Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) No drug interventions treatment 2 terminated NCT02257242
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma No drug interventions treatment 1 completed NCT02169180
Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT01117142
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers No drug interventions Not Available Not Available completed NCT00861510
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies No drug interventions treatment 1 completed NCT00114738
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma treatment 2 completed NCT00025662
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS No drug interventions treatment 2 completed NCT06558604
A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT06045910
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT03682796
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma No drug interventions treatment 1 completed NCT03567876
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL No drug interventions treatment 2 active_not_recruiting NCT03190330
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion No drug interventions other 4 completed NCT03425591
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice No drug interventions Not Available Not Available completed NCT03053024
Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants No drug interventions Not Available Not Available completed NCT02972840
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL No drug interventions treatment 3 active_not_recruiting NCT02413489
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma No drug interventions treatment 2 terminated NCT02419560
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL No drug interventions treatment 1 completed NCT02341781
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment No drug interventions Not Available Not Available completed NCT01367457
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus No drug interventions Not Available Not Available completed NCT00992992
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT00992134
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT00871546
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) No drug interventions treatment 2 terminated NCT00875667
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) No drug interventions treatment 2 completed NCT00700258
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] No drug interventions Not Available Not Available completed NCT00490529
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL No drug interventions treatment 2 completed NCT00261612
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma No drug interventions treatment 2 unknown_status NCT00209222
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL treatment 3 unknown_status NCT00038623
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma treatment 2 completed NCT00005780
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma treatment 2 completed NCT03910283
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer No drug interventions supportive_care Not Available not_yet_recruiting NCT05495464
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma No drug interventions treatment 0 recruiting NCT04802590
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT03494179
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) No drug interventions treatment 1 / 2 active_not_recruiting NCT05694364
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies No drug interventions treatment 1 recruiting NCT05917964
A Food Effect Study of LP-168 Tablets in Healthy Subjects No drug interventions treatment 1 completed NCT03424603
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies No drug interventions treatment 1 completed NCT03028103
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients No drug interventions treatment 1 completed NCT02927964
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma No drug interventions treatment 1 / 2 completed NCT03153202
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) No drug interventions treatment 1 / 2 recruiting NCT02267590
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib No drug interventions Not Available Not Available unknown_status NCT01646021
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy No drug interventions treatment 3 completed NCT01460602
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma No drug interventions treatment 1 / 2 withdrawn NCT00407303
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) No drug interventions treatment 1 / 2 completed NCT02216890
Safety Study of SGN-CD70A in Cancer Patients No drug interventions treatment 1 completed NCT06252675
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma treatment 2 recruiting NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT Scans No drug interventions Not Available Not Available not_yet_recruiting NCT06151730
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study No drug interventions Not Available Not Available recruiting NCT06029309
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma treatment 1 / 2 recruiting NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma treatment 1 recruiting NCT05978739
Evaluating Different Doses of Orelabrutinib in MCL treatment 2 recruiting NCT05934097
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma treatment 1 withdrawn NCT05776134
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel Not Available Not Available available NCT05643742
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas No drug interventions treatment 1 recruiting NCT05076097
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma treatment 2 unknown_status NCT05003141
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies No drug interventions treatment 1 unknown_status NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT04849715
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma treatment 3 withdrawn NCT04783415
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma treatment 2 active_not_recruiting NCT04775745
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. No drug interventions treatment 1 recruiting NCT04765111
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma treatment 2 active_not_recruiting NCT04716075
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) treatment 2 active_not_recruiting NCT04718883
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT04665115
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) treatment 2 withdrawn NCT04599634
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies treatment 1 completed NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas treatment 1 / 2 terminated NCT04323657
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia treatment 1 / 2 completed NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab treatment 1 / 2 active_not_recruiting NCT06341556
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma treatment 2 recruiting NCT06340737
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas No drug interventions treatment 1 recruiting NCT04231734
Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma No drug interventions other Not Available withdrawn NCT04191187
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT04195633
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies treatment 2 recruiting NCT04176913
Study of LUCAR-20S in Patients With R/R NHL No drug interventions treatment 1 terminated NCT04127916
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL) Not Available Not Available unknown_status NCT04082936
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 / 2 terminated NCT03999697
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies No drug interventions treatment 1 unknown_status NCT03842696
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation prevention 1 / 2 recruiting NCT03834688
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age treatment 2 completed NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant treatment 1 / 2 recruiting NCT03601819
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders treatment 1 terminated NCT03523975
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma treatment 1 recruiting NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) treatment 1 / 2 active_not_recruiting NCT04624958
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL treatment 2 recruiting NCT04629430
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT No drug interventions treatment Not Available completed NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers No drug interventions treatment 1 recruiting NCT05255354
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy No drug interventions Not Available Not Available recruiting NCT05444322
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma No drug interventions treatment 0 recruiting NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT04407845
Atrial Fibrillation in Patients Receiving Ibrutinib No drug interventions Not Available Not Available unknown_status NCT03436771
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product No drug interventions Not Available Not Available terminated NCT03267433
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission treatment 3 recruiting NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation treatment 2 active_not_recruiting NCT05432635
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT02756247
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma treatment 1 completed NCT02840539
Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma treatment 2 completed NCT03232307
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma treatment 2 withdrawn NCT03016988
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma treatment 2 unknown_status NCT02793583
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma treatment 2 / 3 terminated NCT02682641
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL No drug interventions treatment 2 active_not_recruiting NCT02446236
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 1 active_not_recruiting NCT02632396
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission No drug interventions treatment 1 / 2 active_not_recruiting NCT02633137
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT02356458
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma No drug interventions treatment 1 / 2 terminated NCT02354313
Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients No drug interventions treatment 3 unknown_status NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib) No drug interventions treatment 3 enrolling_by_invitation NCT01737177
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL No drug interventions treatment 2 completed NCT01685606
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma No drug interventions treatment 2 terminated NCT01597778
Double Cord Versus Haploidentical (BMT CTN 1101) No drug interventions treatment 3 completed NCT01599949
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy No drug interventions treatment 2 completed NCT01562977
Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL No drug interventions treatment 2 completed NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia No drug interventions treatment 1 completed NCT01460134
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers No drug interventions treatment 1 completed NCT01437709
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant No drug interventions treatment 2 completed NCT01263899
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies No drug interventions treatment 2 completed NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT01239875
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 0 completed NCT01111188
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma No drug interventions treatment 1 terminated NCT01000753
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma No drug interventions Not Available Not Available completed NCT00963534
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. No drug interventions treatment 1 / 2 completed NCT00942409
Study of Repeat Intranodal Injections of Ad-ISF35 No drug interventions treatment 2 terminated NCT00901615
Lenalidomide and R-CHOP in B-cell Lymphoma No drug interventions treatment 1 / 2 completed NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease No drug interventions treatment 2 active_not_recruiting NCT00722137
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma No drug interventions treatment 3 completed NCT00581854
Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT00541424
Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma No drug interventions Not Available Not Available withdrawn NCT00446342
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies No drug interventions treatment 1 completed NCT00201877
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma treatment 2 completed NCT00119730
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma treatment 2 completed NCT00063713
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma treatment 2 completed NCT00022945
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma treatment 2 completed NCT04279405
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies No drug interventions treatment 1 completed NCT04043845
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies treatment 1 withdrawn NCT00878254
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers treatment 1 / 2 terminated NCT00186628
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD treatment 2 completed NCT01181271
Tandem Auto-Allo Transplant for Lymphoma No drug interventions treatment 2 completed NCT01497275
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma No drug interventions treatment 2 terminated NCT02661035
Allo HSCT Using RIC for Hematological Diseases No drug interventions treatment 2 completed NCT06553872
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL No drug interventions treatment 2 recruiting NCT06504199
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT06482684
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma No drug interventions treatment 2 recruiting NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. treatment 1 recruiting NCT05724121
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax No drug interventions Not Available Not Available recruiting NCT05486013
Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma No drug interventions Not Available Not Available recruiting NCT05471843
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 1 / 2 recruiting NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia No drug interventions treatment 2 recruiting NCT05164770
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma No drug interventions treatment 3 recruiting NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies No drug interventions treatment 1 terminated NCT05097443
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma No drug interventions treatment 3 recruiting NCT05064787
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy No drug interventions supportive_care Not Available completed NCT05004064
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT04883437
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas No drug interventions treatment 2 recruiting NCT04882475
Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. No drug interventions Not Available Not Available recruiting NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients No drug interventions Not Available Not Available completed NCT04763083
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies No drug interventions treatment 1 recruiting NCT04736914
Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT04491370
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT04402138
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT04368702
CONFIRM: Magnetic Resonance Guided Radiation Therapy No drug interventions treatment Not Available recruiting NCT06324994
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. treatment 2 not_yet_recruiting NCT06339255
Italian Observational Study on CAR-T Therapy for Lymphoma No drug interventions Not Available Not Available recruiting NCT03836768
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma No drug interventions treatment 1 completed NCT04115631
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma treatment 2 active_not_recruiting NCT04116437
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment No drug interventions treatment 2 recruiting NCT03939182
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma treatment 1 active_not_recruiting NCT03891355
Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL No drug interventions treatment 2 unknown_status NCT03863184
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL No drug interventions treatment 2 active_not_recruiting NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) treatment 1 completed NCT03816683
A Disease Registry of Patients With Mantle Cell Lymphoma No drug interventions Not Available Not Available completed NCT03710772
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03676504
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR No drug interventions treatment 1 / 2 recruiting NCT03674411
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy No drug interventions treatment 2 active_not_recruiting NCT03478514
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03617484
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma No drug interventions treatment 2 withdrawn NCT03616782
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) treatment 2 recruiting NCT03623373
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma treatment 2 active_not_recruiting NCT04855695
Avo In R/R And Previously Untreated MCL No drug interventions treatment 1 / 2 recruiting NCT04833504
Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma No drug interventions Not Available Not Available completed NCT05025423
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT05020392
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma No drug interventions treatment 3 recruiting NCT05245656
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma No drug interventions treatment 2 recruiting NCT05458297
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) No drug interventions treatment 2 recruiting NCT05611853
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies No drug interventions treatment 1 / 2 terminated NCT05861050
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma No drug interventions treatment 1 / 2 recruiting NCT05665062
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies treatment 1 recruiting NCT05887167
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies No drug interventions treatment 1 recruiting NCT04419389
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) No drug interventions treatment 1 / 2 terminated NCT03188965
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas treatment 1 completed NCT03151057
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies treatment 1 terminated NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry No drug interventions Not Available Not Available recruiting NCT03311126
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma treatment 2 terminated NCT03272633
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies No drug interventions treatment 0 terminated NCT03128359
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant No drug interventions supportive_care 2 completed NCT03088878
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies No drug interventions treatment 1 / 2 active_not_recruiting NCT04566887
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT02819583
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT02851589
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT02896582
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance treatment 2 active_not_recruiting NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia No drug interventions treatment 2 recruiting NCT03054883
Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy No drug interventions Not Available Not Available completed NCT02728531
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma treatment 1 completed NCT02745769
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents No drug interventions treatment 1 completed NCT02652715
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma No drug interventions basic_science Not Available completed NCT02427620
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT02471391
ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) No drug interventions treatment 2 active_not_recruiting NCT02507336
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 No drug interventions supportive_care 2 completed NCT02483000
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies No drug interventions treatment 1 terminated NCT02268851
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL No drug interventions treatment 1 completed NCT02081937
CART-19 Immunotherapy in Mantle Cell Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT02013128
Ublituximab + Ibrutinib in Select B-cell Malignancies No drug interventions treatment 1 / 2 completed NCT01880567
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT01865110
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL No drug interventions treatment 3 active_not_recruiting NCT01851551
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL No drug interventions treatment 1 / 2 completed NCT01796470
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 2 terminated NCT01739309
Study of LY2835219 for Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT01728207
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL No drug interventions treatment 1 terminated NCT01662050
Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL No drug interventions treatment 2 completed NCT01578343
Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 terminated NCT01456351
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab No drug interventions treatment 3 completed NCT01484093
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT01472562
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT01439750
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) No drug interventions treatment 1 unknown_status NCT01410513
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT01399840
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies No drug interventions treatment 1 completed NCT01314014
Imexon for Relapsed Follicular and Aggressive Lymphomas No drug interventions treatment 2 completed NCT01300026
AMG 319 Lymphoid Malignancy FIH No drug interventions treatment 1 completed NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant No drug interventions treatment 3 completed NCT01251575
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant No drug interventions treatment 2 completed NCT01184885
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy No drug interventions treatment 0 completed NCT01170052
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment 1 / 2 withdrawn NCT01148108
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma No drug interventions treatment 2 completed NCT01078142
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT00992446
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma No drug interventions treatment 2 completed NCT01021423
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). No drug interventions treatment 3 terminated NCT00958256
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab No drug interventions treatment 2 completed NCT00877006
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study No drug interventions treatment 3 completed NCT00847223
Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma No drug interventions treatment 2 terminated NCT00880815
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant No drug interventions treatment 1 completed NCT00791011
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat No drug interventions treatment 1 completed NCT00794638
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT00807495
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma No drug interventions treatment 2 completed NCT00786851
Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) No drug interventions treatment 2 completed NCT00737529
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial No drug interventions treatment 2 completed NCT00714259
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies No drug interventions treatment 2 / 3 terminated NCT00607854
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) No drug interventions treatment 2 completed NCT00633594
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT00612183
Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT00571493
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT00586755
Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT00514475
Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT00505232
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) No drug interventions treatment 2 completed NCT00477412
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT00406809
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies No drug interventions treatment 1 / 2 completed NCT00285389
Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years treatment 2 completed NCT00310037
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma treatment 2 unknown_status NCT00225212
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 2 completed NCT00090090
Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 2 completed NCT00075478
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 3 completed NCT00022971
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia treatment 1 terminated NCT04061850
Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma No drug interventions Not Available Not Available completed NCT03019666
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL treatment 1 completed NCT03112174
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) treatment 3 completed NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT03010982
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors treatment 1 completed NCT01163201
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies No drug interventions treatment 1 / 2 withdrawn NCT02722668
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep No drug interventions treatment 2 active_not_recruiting NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD No drug interventions treatment Not Available terminated NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies No drug interventions treatment 1 / 2 not_yet_recruiting NCT03323151
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies No drug interventions treatment 2 terminated NCT00088205
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma treatment 2 completed NCT02267915
Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT No drug interventions treatment 2 unknown_status NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases No drug interventions treatment Not Available recruiting NCT06572618
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL No drug interventions treatment 1 not_yet_recruiting NCT06522386
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT06363994
A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL No drug interventions treatment 3 not_yet_recruiting NCT06255704
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients No drug interventions treatment 2 not_yet_recruiting NCT06357676
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma No drug interventions treatment 1 / 2 not_yet_recruiting NCT06263491
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients No drug interventions treatment 2 recruiting NCT06208735
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies No drug interventions treatment 1 not_yet_recruiting NCT06049472
Patient Perspectives in Mantle Cell Lymphoma Clinical Research No drug interventions Not Available Not Available not_yet_recruiting NCT06054776
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT06106841
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) No drug interventions treatment 1 / 2 recruiting NCT06004167
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) No drug interventions treatment Not Available recruiting NCT05990465
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies No drug interventions treatment 1 not_yet_recruiting NCT05976763
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma No drug interventions treatment 3 recruiting NCT05934838
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas No drug interventions treatment 1 recruiting NCT05635162
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT05529069
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients No drug interventions treatment 2 recruiting NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader No drug interventions treatment 1 / 2 recruiting NCT04918940
Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma No drug interventions other Not Available completed NCT04844086
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies No drug interventions treatment 1 terminated NCT04600804
The Role of 18F-FDG-PET for Staging and Prognostication No drug interventions Not Available Not Available active_not_recruiting NCT04564040
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole No drug interventions treatment 1 completed NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies No drug interventions treatment 1 completed NCT04223765
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. No drug interventions treatment 1 recruiting NCT04189757
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT04184414
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies No drug interventions treatment 0 unknown_status NCT04109872
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results. No drug interventions Not Available Not Available unknown_status NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 recruiting NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors No drug interventions treatment 1 / 2 active_not_recruiting NCT03872180
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 / 2 active_not_recruiting NCT04692155
Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) No drug interventions treatment 1 / 2 terminated NCT03684694
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma No drug interventions treatment 1 / 2 terminated NCT03685344
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma No drug interventions treatment 1 terminated NCT03629873
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects No drug interventions treatment 2 unknown_status NCT03585725
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma No drug interventions treatment 0 terminated NCT03579927
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma No drug interventions treatment 1 / 2 withdrawn NCT03501576
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma No drug interventions Not Available Not Available recruiting NCT04626791
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT04952974
B-cell Chronic Lymphoid Malignancies Markers No drug interventions Not Available Not Available unknown_status NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms No drug interventions treatment 1 recruiting NCT05833763
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. No drug interventions treatment 2 recruiting NCT03410901
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas No drug interventions treatment 1 active_not_recruiting NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T Cells No drug interventions Not Available Not Available recruiting NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies No drug interventions treatment 1 completed NCT03295240
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma No drug interventions treatment 0 completed NCT03282396
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03229382
Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse No drug interventions treatment 2 terminated NCT05429918
Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years No drug interventions Not Available Not Available unknown_status NCT02735876
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 3 withdrawn NCT02858804
EDOCH Alternating With DHAP for New Diagnosed Younger MCL No drug interventions treatment 4 unknown_status NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients No drug interventions prevention 2 terminated NCT02858258
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma No drug interventions treatment 3 recruiting NCT03019640
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma No drug interventions treatment 2 completed NCT03010358
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT02892695
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT02558816
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients No drug interventions treatment 1 / 2 active_not_recruiting NCT02339922
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma No drug interventions treatment 2 active_not_recruiting NCT02142530
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL No drug interventions treatment 1 completed NCT01799889
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 2 terminated NCT01776840
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma No drug interventions treatment 3 completed NCT01744912
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies No drug interventions treatment 1 terminated NCT01661881
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT01652144
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT01665768
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma No drug interventions treatment 2 completed NCT01504776
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) No drug interventions treatment 1 completed NCT01500538
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) No drug interventions treatment 2 terminated NCT01457144
Study of Mantle Cell Lymphoma Treatment by RiBVD No drug interventions treatment 2 completed NCT01449344
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL No drug interventions treatment 3 unknown_status NCT01397825
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine No drug interventions treatment 1 / 2 completed NCT01236391
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) No drug interventions treatment 2 completed NCT01109069
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT01088048
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT01073163
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) No drug interventions treatment 3 completed NCT00980395
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma No drug interventions treatment 2 completed NCT00921414
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance No drug interventions treatment 3 completed NCT00891839
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT00843050
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 terminated NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT00609869
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab No drug interventions treatment 2 completed NCT00581776
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT00472420
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. No drug interventions treatment 2 completed NCT00275262
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation No drug interventions treatment 2 terminated NCT00275431
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies treatment 2 completed NCT00183989
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma treatment 2 terminated NCT00081874
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma treatment 1 / 2 completed NCT00946374
Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma No drug interventions treatment 2 unknown_status NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine No drug interventions treatment 1 active_not_recruiting NCT02631044
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) No drug interventions treatment 1 completed NCT00783367
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas No drug interventions treatment 2 completed NCT05888701
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. No drug interventions Not Available Not Available recruiting NCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies No drug interventions treatment 1 / 2 completed NCT05868395
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT02991638
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers No drug interventions treatment 3 unknown_status NCT04994587
Study of LUCAR-20S in Patients With R/R NHL No drug interventions treatment 1 recruiting NCT03420183
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies treatment 1 / 2 recruiting NCT00877214
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas No drug interventions treatment 3 active_not_recruiting NCT05406154
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years No drug interventions Not Available Not Available unknown_status NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T No drug interventions other 1 enrolling_by_invitation NCT05144347
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT04002297
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma treatment 3 active_not_recruiting NCT06464861
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma No drug interventions treatment 1 not_yet_recruiting NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML treatment 1 recruiting NCT05951959
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma treatment 2 active_not_recruiting NCT04049513
ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) treatment 1 active_not_recruiting NCT03265158
Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 No drug interventions Not Available Not Available unknown_status NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies No drug interventions treatment 1 / 2 active_not_recruiting NCT04477486
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma treatment 2 active_not_recruiting NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies treatment 1 recruiting NCT02213926
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT04767308
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies No drug interventions treatment 0 unknown_status NCT05716087
A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT03571828
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma No drug interventions treatment 1 terminated NCT06043011
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms No drug interventions Not Available Not Available recruiting NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 / 2 terminated NCT03869619
REal World Data in LYmphoma and Survival in Adults No drug interventions Not Available Not Available recruiting NCT02717624
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL No drug interventions treatment 1 active_not_recruiting NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment No drug interventions Not Available Not Available completed NCT03877055
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT06496308
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment No drug interventions treatment 3 recruiting NCT02914938
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT00697346
Study of MLN8237 in Participants With Advanced Hematological Malignancies No drug interventions treatment 1 completed NCT02650999
Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas No drug interventions treatment 1 / 2 completed